The stock of Epizyme Inc (NASDAQ:EPZM) is a huge mover today! About 301,622 shares traded hands or 8.33% up from the average. Epizyme Inc (NASDAQ:EPZM) has declined 8.56% since April 13, 2016 and is downtrending. It has underperformed by 12.49% the S&P500.
The move comes after 7 months negative chart setup for the $647.41 million company. It was reported on Nov, 15 by Barchart.com. We have $10.62 PT which if reached, will make NASDAQ:EPZM worth $38.84M less.
Epizyme Inc (NASDAQ:EPZM) Ratings Coverage
Out of 7 analysts covering Epizyme (NASDAQ:EPZM), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Epizyme has been the topic of 9 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Mizuho on Thursday, August 6. The stock of Epizyme Inc (NASDAQ:EPZM) earned “Buy” rating by H.C. Wainwright on Monday, March 14. The stock of Epizyme Inc (NASDAQ:EPZM) has “Buy” rating given on Tuesday, August 25 by Zacks. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, September 28. Mizuho maintained it with “Buy” rating and $18 target price in Tuesday, May 10 report. On Tuesday, April 5 the stock rating was initiated by Citigroup with “Buy”. JMP Securities maintained it with “Market Outperform” rating and $28 target price in Wednesday, March 9 report.
According to Zacks Investment Research, “Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.64 in 2016 Q2. Its down 1.17, from 2.81 in 2016Q1. The ratio is negative, as 8 funds sold all Epizyme Inc shares owned while 20 reduced positions. 14 funds bought stakes while 32 increased positions. They now own 45.74 million shares or 3.00% more from 44.40 million shares in 2016Q1.
Moreover, State Bank Of Ny Mellon has 0% invested in Epizyme Inc (NASDAQ:EPZM) for 169,352 shares. Franklin Resource has 0.01% invested in the company for 1.20M shares. Woodstock Corporation accumulated 0.06% or 27,534 shares. Great West Life Assurance Can accumulated 0% or 4,800 shares. Secor Cap Advisors Ltd Partnership owns 60,556 shares or 0.08% of their US portfolio. Legal And General Group Pcl holds 0% of its portfolio in Epizyme Inc (NASDAQ:EPZM) for 7,475 shares. The Iowa-based Principal Group has invested 0% in Epizyme Inc (NASDAQ:EPZM). Zacks Investment Management holds 17,003 shares or 0.01% of its portfolio. Baker Bros Advisors Lp has 0.02% invested in the company for 232,481 shares. Blackrock Fund Advisors holds 1.69M shares or 0% of its portfolio. Macquarie Gru Limited reported 20,000 shares or 0% of all its holdings. Blackrock Advisors Limited Co has 18,879 shares for 0% of their US portfolio. Nationwide Fund Advsrs last reported 26,156 shares in the company. Trexquant Inv Lp holds 0.05% or 37,801 shares in its portfolio. Jennison Assocs Limited Liability Company holds 0.02% or 1.78M shares in its portfolio.
Insider Transactions: Since June 9, 2016, the stock had 0 buys, and 8 insider sales for $141,970 net activity. 1,013 shares were sold by Singer Andrew E., worth $10,535. 4,000 shares with value of $41,492 were sold by Copeland Robert A on Monday, August 1.
More important recent Epizyme Inc (NASDAQ:EPZM) news were published by: Fool.com which released: “Why Epizyme Inc, Akebia Therapeutics Inc, and Cempra Inc Got Wacked Today” on January 07, 2016, also Businesswire.com published article titled: “Epizyme Announces Pricing of Public Offering of Common Stock”, Businesswire.com published: “Epizyme Announces Closing of Public Offering of Common Stock” on January 12, 2016. More interesting news about Epizyme Inc (NASDAQ:EPZM) was released by: Businesswire.com and their article: “Epizyme Announces Proposed Public Offering of Common Stock” with publication date: January 05, 2016.
EPZM Company Profile
Epizyme, Inc., incorporated on November 1, 2007, is a clinical-stage biopharmaceutical company. The Firm discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. The Firm develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs. The Firm develops small molecule inhibitors of other chromatin modifying proteins, or CMPs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.